News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QSV Biologics, Ltd. and, ALSERES Pharmaceuticals, Inc. (ALSE) Sign Contract for cGMP Manufacture of Cethrin(R) for Spinal Cord Injury



7/10/2007 3:11:42 PM

EDMONTON, July 10 /CNW/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, and Alseres Pharmaceuticals, Inc., (Alseres) a publicly traded (Nasdaq: ALSE - News) Central Nervous System diagnosis and treatment company located in Hopkinton, Massachusetts, U.S.A., announced today the signing of a contract for the process development and cGMP manufacturing of Cethrin(R) for spinal cord injury. QSV will be responsible for technology transfer, process development and cGMP manufacture of phase IIb/III clinical trial material in their commercially licensed cGMP manufacturing facility. Cethrin(R), licensed by Alseres from BioAxone Therapeutics, is a Rho inhibitor that stimulates axon regeneration.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES